Neovacs S.A Ret. on assets
What is the Ret. on assets of Neovacs S.A?
The Ret. on assets of Neovacs S.A. is -9.79%
What is the definition of Ret. on assets?
Return on assets indicates how profitable a company’s assets are in generating revenue. It is computed by dividing net income by average total assets.
ttm (trailing twelve months)
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
Ret. on assets of companies in the Health Care sector on EURONEXT compared to Neovacs S.A
What does Neovacs S.A do?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Companies with ret. on assets similar to Neovacs S.A
- Resort Savers has Ret. on assets of -9.83%
- Solitario Zinc has Ret. on assets of -9.81%
- Fonterra Shareholders Fund has Ret. on assets of -9.81%
- Mauna Kea Technologies SA has Ret. on assets of -9.81%
- Linekong Interactive Co has Ret. on assets of -9.80%
- Predictive Discovery has Ret. on assets of -9.79%
- Neovacs S.A has Ret. on assets of -9.79%
- TRX Gold Corp has Ret. on assets of -9.79%
- Pfenex has Ret. on assets of -9.78%
- M8 Sustainable has Ret. on assets of -9.78%
- M8 Sustainable has Ret. on assets of -9.78%
- Rio2 has Ret. on assets of -9.77%
- Goldstrike Resources has Ret. on assets of -9.77%